• Nenhum resultado encontrado

BIBLIOGRAFIA CONSULTADA

No documento GUIA DE CONDUTAS TRANSFUSIONAIS (páginas 51-55)

LANGHI JÚNIOR, Dante Mário; BORDIN, José Orlando; COVAS, DT. Hemoterapia Fundamentos e Prática. São Paulo: Atheneu, 2006, v.1. p.658

FABRON JÚNIOR, Antonio, LANGHI JÚNIOR, Dante Mário, BORDIN, José Orlando. Indicações e Cuidados nas Transfusões de Hemocomponentes e Hemoderivados. São Paulo: JCLine 2001, p.37 Blacjchman MA, Bordin JO, Bardossy LA ET AL. The contribution of the hematócrito to thrombocytopenic bleeding in experimental animals. Br J Hematol 1994; 86:347-50.

Blat PM, Lundblad RL, Kingdon HS, et al. Thrombogenic material in prothrmbin complex concentrates.

Ann Intern Med 1974; 81:766-70.

Bordin JO, Fabron AJ. Aplicação clínica de filtros leucocitários. Ver Ass Med Brasil 1997; 43(3): 205-8.

Braine HG, Kickler TS, Charache P, ET AL. Bacterial sepsis secondary to palet transfusion: An adverse effect of extended storage at room temperature. Transfusion 1986; 26:391-3.

Carson JL, Hill S, Carless P et al. Transfusion triggers: a systematic review of the literature. Transf Med Revuew 2002; 16(3):187-99.

Chiattone CS, Cançado RD. Plaquetas: quando transfundir? Bol. Soc. Bras. Hematol. Hemot. 1993;

15(162): 1-2.

Consensus conference. Fresh-frozen plasma. Indication and risk. JAMA 1985; 253:551-3.

Consensus conference. Platelet transfusion therapy. JAMA 1987; 257: 1777-80.

Couban S, Carruthers J, Andreou P et al. Platelet transfusion in children: results of a randomizied, prospective, crossover trial of plasma removal and propective audit os WBC reduction. Transfusion 2002; 42:753-8.

Diretrizes para a Transfusão de Albumina. Agência Nacional de Vigilância Sanitária – ANVISA/MS.

Resolução RDC nº 115, de 20 de maio de 2004, Diário Oficial da União de 21 de maio de 2004.

Diretrizes para a Transfusão de Hemácias. Agência Nacional de Vigilância Sanitária – ANVISA/MS.

Consulta Pública nº 37, de 20 de maio de 2004, Diário Oficial da União de 21 de maio de 2004.

Diretrizes para a Transfusão de imunoglobulinas. Agência Nacional de Vigilância Sanitária – ANVISA/MS. Consulta Pública nº 36, Diário Oficial da União de maio de 2004.

Diretrizes para a Transfusão de Plasma fresco. Agência Nacional de Vigilância Sanitária – ANVISA/MS. Resolução RDC nº 10, de 23 de janeiro de 2004, Diário Oficial da União 26 de janeiro de 2004.

Diretrizes para a Transfusão de Plaquetas. Agência Nacional de Vigilância Sanitária – ANVISA/MS.

Resolução RDC nº 129, de 24 de maio de 2004, Diário Oficial da União de 25 de maio de 2004.

Dodd RY. The risk of transfusion-transmitted infection. N. Engl Med 1992; 327: 139-44.

Erstad BL, Gales B, Rapapport WD. The used of albumin in clinical practice. Arch Intern Med 1991;

151:901.

Foley EF, Borlase BC, Dzik WH et al. Albumin supplementation in the critical ill. A prospective, randomized trial. Arch Surg 1990; 25:739-42.

Friedmann AM, Segunl H, Lehmann et al. No basic laboratory tests or clinical observations predict bleending in thrombocytopenic oncology patients? A revolution of prophylactic transfusion. Trans Med Rev 2002; 16:32-45.

Gentilini P, Casini-Raggi V, Di Fiore G et al. Albumin improves the response of diuretics in patients wuth cirrhosis and ascites: results of a randomized, controlled trial. J. Hepatol 1999; 30:639-45.

Godeau B, Chevret S, Varet B et al. Intravenous Immunoglobulin or high-dose methylprednisolone, with or without oral prednisone for adults with untreated severe autoimmune thrombocytopenic purpura: a randomized, multicentre trial. Lancet 2002; 359:23-9.

Goodnough LT, Shander A, Spence R. Bloodless medicine: clinical care without allogeneic blood transfusion. Transfusion 2003; 43(5): 668-76.

Grocott MPW, Hamilton MA. Resuscitation fluid. Vox Sang 2002; 82:1-8.

Guideline for the clinical use of the red transfusions. Br J Haematol 2001; 113:24-1.

Kao KJ. Mechanisms and new approaches for the Allogenic Blood Transfusion Induced Immunodulatory Effects. Transfus Med Ver 2000; 14(1): 12-22.

Knezevic-Meramica I, Kruskall MS. Intravenous immune globulins: an update for clinicians. Transfusion 2003; 43:1460-80.

Lowe RJ, Moss GS, Jilek J, Levine HD. Crystalloid vs colloid in the etiology os pulmonary failure after trauma: a randomized trial in man. Sugery 1977; 81:676-83.

Lusher JM. Thrombogenicity associated with factor IX complex concentrates. Semin Hematol. 1991; 28 (Suppl 6):3-4.

McVay. Toy PTCY. Lack of increased bleeding after parecentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion 1991; 31:164-71.

Owen HG, Brecher ME. Management of the therapeutic apheresis patient. In: Mc Leod BC, Price TH, Drew MJ, eds Apheresis: Principles and practice. Bethesda, MD: AABB Press, 1997:225-6.

Patten E. Prophylactic Platelet Transfusion revisited after 25 years: con. Transfusion 1992; 32:381-5.

Redeghiero F, Catman G, Dini E. Epidemiologic investigation of the prevalence of von Willebrand’s disease. Blood 987; 69:454.

Royal College of Physicians os Edinburg Consensus Conference on Platelet Transfusion. Transfusion Medicine. 1998; 8:149-51.

Schiffer CA, Anderson KC, Bennett CL et al. Platelet transfusion for patients with cancer: clinical practice guidelines of thr American Society of Clinical Oncology. J Clin Oncol 2001; 19:1519-38.

Schuman S, Matinowitz U. Design and assessment of clinical trials on continuous infusion. Blood Coagul Fibrinolysis 1996; 7 (Suppl 1): S7-9.

Simon TL, Aki Bechara F, Murphy W. Controlled trial of routine administration of platelet concentrates in cardiopulmonary bypass surgery. Ann Thorac Surg 1984; 37:359.

Stehling L, Luban NLC, Anderson KC, Sayers MH, Long A, Attar S, Leitman SF, Gould AS, Krukall MS, Goodnough LT, Hines DM. Guidelines for blood utilization review. Transfusion 1994; 34(5): 438-48.

Strauss R, Ciavarella D, Gilcher R. Na overview of current management. J Clin Apheresis 1993; 8:189-94.

Strauss RG. Therapeutic granulocyte transfusion in 1993; 81:1675-8.

Strauss RG. Clinical perspectives of platelet transfusion: Defining the optimal dose. J Clin Apher 1995; 10:124-7.

The Saline versus albumin fluid evaluation (SAFE) study: design and conduct of a multi-centric blinded randomized controlled trial of intravenous fluid resuscitation in critically ill patients. BMJ 2003; 326-559 data supplement.

Urban J. Inglis AS, Edwards K: Clinical evidence for the difference between albumins from microssomes and serum and a possible precursor product relationship. Biochem Biophys Res Commun 1974; 61:444.

Vengelen-Tyler V. Technical Manual 12 ed. Bethesda, American Association of Blood Banks, 1996. P 135-56.

Vehar GA, Keyt B, Eaton D, et al Structure of human factor VIII. Nature 1984; 312:337-42.

Vicent JL, Dubois MJ, Navickis RJ et al. Hypoalbuminemia in acute illness: is there a rational for intervention? A meta-anlysis of cohort studies and control trials. Ann Surg 2003; 237:319-34.

Woodson RD, Auerbach S. Effect of increased oxygen affinity and anemia on cardiac output and its distribution. J Appl Physiol. 1982;53:1299-306.

No documento GUIA DE CONDUTAS TRANSFUSIONAIS (páginas 51-55)

Documentos relacionados